Clinical case: renal tumor with succinate dehydrogenase deficiency during pregnancy
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20243198Keywords:
RCC, Pregnancy, SDH deficiency, NephrectomyAbstract
Renal tumors during pregnancy present unique challenges due to the need to balance maternal and fetal health considerations. This case report describes a 31-year-old pregnant woman diagnosed with succinate dehydrogenase (SDH)-deficient renal cell carcinoma (RCC) during the second trimester. The patient presented with lumbar pain and hematuria, leading to the discovery of a left renal mass that was surgically removed via radical nephrectomy, with histopathological analysis confirming SDH-deficient RCC, stage 1. Postoperative care involved anticoagulation therapy, fetal heart rate monitoring and close follow-up. These tumors demand a multidisciplinary approach, with diagnostic tools like ultrasound and MRI to minimize fetal exposure to radiation. SDH-deficient renal tumors, a rare subtype of RCC, requires precise, that requires precise diagnosis due to their association with tumors such as paragangliomas and pheochromocytomas. Treatment strategies, including surgical intervention, are typically tailored to the tumor's characteristics, symptoms, the patient’s wishes and the pregnancy stage, being the second trimester the safest period for surgery. Discussion highlights the importance of individualized care and a collaborative medical approach for optimal outcomes for mother and fetus. Managing renal tumors during pregnancy is complex, requiring careful consideration of maternal and fetal health. A multidisciplinary approach, timely surgical intervention, and individualized treatment plans are essential for optimizing outcomes. Second trimester is often the safest time for surgery, with more aggressive treatments deferred until after delivery, depending on tumor's characteristics and pregnancy stage. This case underscores importance of tailored strategies to ensure the best prognosis for mother and child.
Metrics
References
Attalla K, Weng S, Voss MH, Hakimi AA. Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. Urol Clin North Am. 2020;47(3):293-303.
Msaouel P, Genovese G, Tannir NM. Renal Cell Carcinoma of Variant Histology: Biology and Therapies. Hematol Oncol Clin North Am. 2023;37(5):977-92.
Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022;39(3):2022.
Zhao Y, Yang Z, Xu W, Ji Z, Dong J. Management of renal tumors during pregnancy: case reports. BMC Nephrol. 2021;22(1):127.
Caglayan A, Rabbani RD, Sanchez E, Choi S, Ismail A, Papadopoulos V, et al. Gestational Renal Cell Cancer - An Update. Anticancer Res. 2023;43(9):3871-80.
Boussios S, Pavlidis N. Renal cell carcinoma in pregnancy: a rare coexistence. Clin Transl Oncol. 2014;16(2):122-7.
Maggen C, Linssen J, Gziri MM, Zola P, Cardonick E, de Groot CJM, et al. Renal and Bladder Cancer During Pregnancy: A Review of 47 Cases and Literature-based Recommendations for Management. Urology. 2021;151:118-28.
Caño Velasco J, Polanco Pujol L, Hernandez Cavieres J, González García FJ, Herranz Amo F, Ciancio G, et al. Controversies in the diagnosis of renal cell carcinoma with tumor thrombus. Actas Urol Esp (Engl Ed). 2021;45(4):257-63.
Higashi S, Sasaki T, Uchida K, Kageyama T, Ikejiri M, Matsumoto R, et al. Succinate dehydrogenase B-deficient renal cell carcinoma with a germline variant in a Japanese patient: a case report. Hum Genome Var. 2022;9:25.
Kumar RA, Miyagi H, Mittal V, Crispen P, Kumar U. Succinate dehydrogenase deficient renal cell carcinoma: A case report. Urology Case Reports. 2022;40:101885.
Zambrana F, Barbancho C, Huelves M, García de Santiago B, Martín Y, Muñoz de Lengaria M, et al. Successful Pregnancy and Cancer Outcomes With Ipilimumab and Nivolumab for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature. J Immunother. 2023;46(1):27-8.